Former Shire asset becomes Mirum’s first FDA-approved rare disease drug September 30, 2021 Auto Bot BioPharma, biopharma nl, California, Clinical Trials, FDA, Foster City, Legal, Pharma, Rare diseases 0 Mirum Pharmaceuticals drug Livmarli is now approved to treat pruritus caused by Alagille syndrome, a rare liver disease that can worsen to the point of requiring a transplant. Mirum licensed the drug from Shire in 2018.